Primate Monocytes - CD14, CD16 - Ziegler-Heitbrock


Flow cytometric assessment of leukemia-associated monocytes in childhood B-cell acute lymphoblastic leukemia outcome.


Relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) remains a leading cause of cancerrelated death in children.1,2 Despite an extensive understanding of leukemia-intrinsic drivers of disease relapse,3 the role of the leukemia microenvironment in promoting leukemic blast survival remains unclear.4 To address this, we and others have shown B-ALL blasts significantly remodel the immune microenvironment composition, particularly increasing representation of nonclassical monocytes (ncMono; CD14–CD16+) within the leukemia-associated myeloid compartment.5-7 Previous studies suggest classical monocytes give rise to ncMonos8,9 that can then act, in part, to maintain vascular endothelial integrity,10 however, the specific function of ncMonos in B-ALL pathogenesis remains unclear. Furthermore, we demonstrated that high monocyte abundance in peripheral blood (PB) at initial diagnosis was associated with an inferior outcome in both adults and children with B-ALL. These initial studies used single cell RNA-sequencing analysis on a small cohort of patients with diagnosis, remission, and relapse B-ALL biospecimens; however, we did not analyze individuals who achieved prolonged disease remission and relied on total monocyte abundance as a surrogate marker of ncMono. To validate the association of ncMono in a much larger cohort of B-ALL diagnosis samples, we examined the relationship between bone marrow (BM) and PB ncMono, and to specifically study the prognostic impact of ncMono, we performed high-parameter flow cytometry on primary matched B-ALL diagnosis BM and PB from children enrolled in the Children’s Oncology Group (COG) protocols.

Authors: Contreras Yametti GP, Evensen NA, Schloss J, Aldebert C, Duan E, Zhang Y, Hu J, Chambers TM, Scheurer ME, Teachey DT, Rabin KR, Raetz EA, Aifantis I, Carroll WL, Witkowski MT,
Journal: Blood Adv;2023May17. doi:10.1182/bloodadvances.2023010044
Year: 2023
PubMed: PMID: 37196626 (Go to PubMed)